Etesamine is an appropriate substance for the treatment of depression resistant to other treatments, in adults, which should be used in combination with another oral antidepressant.
This drug is not yet marketed in Brazil, but has already been approved by the FDA to be marketed in the United States, under the trade name Spravato, for intranasal administration.
- Sethamine is a drug that must be administered intranasally.
- Combined with an oral antidepressant.
- For the treatment of depression resistant to other treatments.
This medicinal product should be administered intranasally, under the supervision of a health care professional, who should monitor blood pressure before and after administration.
Spravato should be administered twice a week for 4 weeks, the first dose should be 56 mg and the next dose may be 56 mg or 84 mg, then from the fifth to the eighth week, the recommended dose is 56 mg or 84 mg.once a week, and as of the ninth week, 56 mg or 84 mg can only be administered every 2 weeks, or at the discretion of the doctor.
The nasal atomizer releases only 2 doses with a total of 28 mg of sceamine, so a dose is placed in each nostril, so to receive a dose of 56 mg 2 devices should be used, and for a dose of 84 mg, 3 devices should be used and it is necessary to wait about 5 minutes between each use.
This remedy is contraindicated in people with hypersensitivity to the components of the formula, in people with aneurysms, arteriophaseal malformations or with a history of intracerebral hemorrhage.
Some of the most common side effects that can occur with the use of sceamine are dissociation, dizziness, nausea, sedation, dizziness, decreased sensitivity in certain areas of the body, anxiety, lethargy, increased blood pressure, vomiting and feeling intoxicated.